Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Clinical trial NCT02861417 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02861417
Sponsor: M.D. Anderson Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Hematopoietic and Lymphoid Cell Neoplasm High Risk Acute Myeloid Leukemia High Risk Myelodysplastic Syndrome Lymphoproliferative Disorder Myelodysplastic Syndrome Myelodysplastic/Myeloproliferative Neoplasm Recurrent Acute Lymphoblastic Leukemia Recurrent Acute Myeloid Leukemia Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recurrent High Risk Myelodysplastic Syndrome Recurrent Hodgkin Lymphoma Recurrent Myelodysplastic Syndrome

Start date: 2016-08-05
Primary completion: 2028-08-31
Enrollment: 204

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.